These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Treatment with the selective PDE4B inhibitor A-33 or PDE4D inhibitor zatolmilast prevents sleep deprivation-induced deficits in spatial pattern separation. Zhao H; Blokland A; Prickaerts J; Havekes R; Heckman PRA Behav Brain Res; 2024 Feb; 459():114798. PubMed ID: 38056709 [TBL] [Abstract][Full Text] [Related]
3. Effects of tadalafil (PDE5 inhibitor) and roflumilast (PDE4 inhibitor) on airway reactivity and markers of inflammation in ovalbumin-induced airway hyperresponsiveness in guinea pigs. Mokry J; Urbanova A; Medvedova I; Kertys M; Mikolka P; Kosutova P; Mokra D J Physiol Pharmacol; 2017 Oct; 68(5):721-730. PubMed ID: 29375047 [TBL] [Abstract][Full Text] [Related]
4. The Phosphodiesterase-4 Inhibitor Roflumilast, a Potential Treatment for the Comorbidity of Memory Loss and Depression in Alzheimer's Disease: A Preclinical Study in APP/PS1 Transgenic Mice. Wang H; Zhang FF; Xu Y; Fu HR; Wang XD; Wang L; Chen W; Xu XY; Gao YF; Zhang JG; Zhang HT Int J Neuropsychopharmacol; 2020 Dec; 23(10):700-711. PubMed ID: 32645141 [TBL] [Abstract][Full Text] [Related]
5. Dose dependent effects of tadalafil and roflumilast on ovalbumin-induced airway hyperresponsiveness in guinea pigs. Urbanova A; Medvedova I; Kertys M; Mikolka P; Kosutova P; Mokra D; Mokrý J Exp Lung Res; 2017; 43(9-10):407-416. PubMed ID: 29220595 [TBL] [Abstract][Full Text] [Related]
7. Sub-efficacious doses of phosphodiesterase 4 and 5 inhibitors improve memory in a mouse model of Alzheimer's disease. Gulisano W; Tropea MR; Arancio O; Palmeri A; Puzzo D Neuropharmacology; 2018 Aug; 138():151-159. PubMed ID: 29885420 [TBL] [Abstract][Full Text] [Related]
8. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629 [TBL] [Abstract][Full Text] [Related]
9. Roflumilast: A potential drug for the treatment of cognitive impairment? Sugin LJS; Murugesan A; Bindu M; Sunil KN Neurosci Lett; 2020 Sep; 736():135281. PubMed ID: 32735939 [TBL] [Abstract][Full Text] [Related]
10. Pharmacological mechanism of roflumilast in the treatment of asthma-COPD overlap. Zhang X; Chen Y; Fan L; Ye J; Fan J; Xu X; You D; Liu S; Chen X; Luo P Drug Des Devel Ther; 2018; 12():2371-2379. PubMed ID: 30122895 [TBL] [Abstract][Full Text] [Related]
12. Effects of rolipram and roflumilast, phosphodiesterase-4 inhibitors, on hypertension-induced defects in memory function in rats. Jabaris SG; Sumathy H; Kumar RS; Narayanan S; Thanikachalam S; Babu CS Eur J Pharmacol; 2015 Jan; 746():138-47. PubMed ID: 25446433 [TBL] [Abstract][Full Text] [Related]
13. Roflumilast promotes memory recovery and attenuates white matter injury in aged rats subjected to chronic cerebral hypoperfusion. Santiago A; Soares LM; Schepers M; Milani H; Vanmierlo T; Prickaerts J; Weffort de Oliveira RM Neuropharmacology; 2018 Aug; 138():360-370. PubMed ID: 29933009 [TBL] [Abstract][Full Text] [Related]
14. [Novel trends in pharmacotherapy of chronic obstructive pulmonary disease--prevention of exacerbations (focus on roflumilast)]. Sinopal'nikov AI Klin Med (Mosk); 2014; 92(2):57-64. PubMed ID: 25269184 [TBL] [Abstract][Full Text] [Related]
15. The glucose-lowering effects of the PDE4 inhibitors roflumilast and roflumilast-N-oxide in db/db mice. Vollert S; Kaessner N; Heuser A; Hanauer G; Dieckmann A; Knaack D; Kley HP; Beume R; Weiss-Haljiti C Diabetologia; 2012 Oct; 55(10):2779-2788. PubMed ID: 22790061 [TBL] [Abstract][Full Text] [Related]
16. Phosphodiestrase-1 and 4 inhibitors ameliorate liver fibrosis in rats: Modulation of cAMP/CREB/TLR4 inflammatory and fibrogenic pathways. Essam RM; Ahmed LA; Abdelsalam RM; El-Khatib AS Life Sci; 2019 Apr; 222():245-254. PubMed ID: 30858122 [TBL] [Abstract][Full Text] [Related]
17. How phosphodiesterase 4 inhibitors work in patients with chronic obstructive pulmonary disease of the severe, bronchitic, frequent exacerbator phenotype. Giembycz MA; Newton R Clin Chest Med; 2014 Mar; 35(1):203-17. PubMed ID: 24507847 [TBL] [Abstract][Full Text] [Related]
18. Acute administration of roflumilast enhances immediate recall of verbal word memory in healthy young adults. Van Duinen MA; Sambeth A; Heckman PRA; Smit S; Tsai M; Lahu G; Uz T; Blokland A; Prickaerts J Neuropharmacology; 2018 Mar; 131():31-38. PubMed ID: 29241652 [TBL] [Abstract][Full Text] [Related]
19. The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease. Cazzola M; Calzetta L; Rogliani P; Matera MG Expert Opin Drug Discov; 2016 Jul; 11(7):733-44. PubMed ID: 27169612 [TBL] [Abstract][Full Text] [Related]
20. Roflumilast in the management of chronic obstructive pulmonary disease. Lipari M; Benipal H; Kale-Pradhan P Am J Health Syst Pharm; 2013 Dec; 70(23):2087-95. PubMed ID: 24249758 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]